| 127.93 -5.48 (-4.11%) | 11-20 16:00 | |||||||||||||
|
|
| Short term | ||||
| Mid term | ||||
| Targets | 6-month : | 155.82 |
1-year : | 166.94 |
| Resists | First : | 133.41 |
Second : | 142.92 |
| Pivot price | 131.14 |
|||
| Supports | First : | 118.01 |
Second : | 98.18 |
| MAs | MA(5) : | 133.56 |
MA(20) : | 130.92 |
| MA(100) : | 119.58 |
MA(250) : | 102.28 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 60.3 |
D(3) : | 66.6 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 144.35 | Low : | 69.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MLAB ] has closed above bottom band by 36.8%. Bollinger Bands are 38.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 133.99 - 134.89 | 134.89 - 135.63 |
| Low: | 125.06 - 125.91 | 125.91 - 126.61 |
| Close: | 126.68 - 128.07 | 128.07 - 129.21 |
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Thu, 12 Nov 2026
Mesa Laboratories (MLAB) counsel’s stock units start vesting at 34% on November 10, 2027. - Stock Titan
Mon, 09 Nov 2026
Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript - The Motley Fool
Mon, 09 Nov 2026
Mesa Labs: Fiscal Q2 Earnings Snapshot - KVUE
Mon, 09 Nov 2026
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance - Yahoo Finance
Mon, 09 Nov 2026
What Mesa Laboratories (MLAB) Said on Its Q2 Earnings Call - TradingView
Mon, 09 Nov 2026
Mesa Laboratories, Inc. Q2 2027 Earnings Call Summary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 101.2 (%) |
| Shares Short | 391 (K) |
| Shares Short P.Month | 404 (K) |
| EPS | 0.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.72 |
| Profit Margin | 1.9 % |
| Operating Margin | 11.6 % |
| Return on Assets (ttm) | 3.2 % |
| Return on Equity (ttm) | 2.6 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 28.63 |
| Sales Per Share | 44.59 |
| EBITDA (p.s.) | 8.11 |
| Qtrly Earnings Growth | -42.5 % |
| Operating Cash Flow | 56 (M) |
| Levered Free Cash Flow | 53 (M) |
| PE Ratio | 150.5 |
| PEG Ratio | 0 |
| Price to Book value | 3.79 |
| Price to Sales | 2.86 |
| Price to Cash Flow | 12.86 |
| Dividend | 0.15 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |